Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
About this item
Full title
Author / Creator
Gao, Xue , Tao, Yong , Lamas, Veronica , Huang, Mingqian , Yeh, Wei-Hsi , Pan, Bifeng , Hu, Yu-Juan , Hu, Johnny H. , Thompson, David B. , Shu, Yilai , Li, Yamin , Wang, Hongyang , Yang, Shiming , Xu, Qiaobing , Polley, Daniel B. , Liberman, M. Charles , Kong, Wei-Jia , Holt, Jeffrey R. , Chen, Zheng-Yi and Liu, David R.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
CRISPR–Cas9 genome editing is used to correct a dominant-negative mutation in a mouse model of inherited deafness, resulting in improvements in cochlear function and hearing.
Hindering heritable hearing loss
Nearly half of all deafness cases arise from genetic factors, yet there are limited treatment options available for inherited hearing lo...
Alternative Titles
Full title
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5784267
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5784267
Other Identifiers
ISSN
0028-0836
E-ISSN
1476-4687
DOI
10.1038/nature25164
